Joseph A. Sparano
Albert Einstein College of Medicine
522 Papers
4.4K Citations
Joseph A. Sparano is an academic researcher from Albert Einstein College of Medicine. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 71, co-authored 458 publications. Previous affiliations of Joseph A. Sparano include Montefiore Medical Center & Eastern Cooperative Oncology Group.
Chat about Author
Papers
Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-5103
Bryan P. Schneider,Fei Shen,Guanglong Jiang,Anne O'Neill,Milan Radovich,Lang Li,Laura Gardner,Dongbing Lai,Tatiana Foroud,Joseph A. Sparano,George W. Sledge,Kathy D. Miller +11 more
- 21 Aug 2017
TL;DR: This paper evaluated the impact of genetically determined ancestry on disparity in efficacy and therapy-induced toxicity for patients with breast cancer in the context of a randomized, phase III adjuvant trial.
32
Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205
Tianhong Li,Paul J. Christos,Joseph A. Sparano,Dawn L. Hershman,S. Hoschander,Katie M. O'Brien,John J. Wright,Linda T. Vahdat +7 more
TL;DR: The target CBR of 70% for the tipifarnib-fulvestrant combination in HR-positive MBC was set too high and was not achieved, and the 48% CBR in AI-resistant disease compares favorably with the 32%CBR observed with fulvestrant alone in prior studies and merit further clinical and translational evaluation.
31
Taxanes: impact on breast cancer therapy.
TL;DR: A review of pivotal trials evaluating taxane therapy that have informed the current approach for the use of taxanes in early-stage and advanced-stage breast cancer is provided.
31
Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100
Bryan P. Schneider,Lang Li,Fei Shen,Kathy D. Miller,Milan Radovich,A O'Neill,Robert Gray,D. Lane,David A. Flockhart,Guanglong Jiang,Z. Wang,Dongbing Lai,Daniel L. Koller,J. H. Pratt,Chau T. Dang,Donald W. Northfelt,Edith A. Perez,Tamara Shenkier,Melody A. Cobleigh,Mary Lou Smith,Elda Railey,Ann H. Partridge,Julie R. Gralow,Joseph A. Sparano,Nancy E. Davidson,Tatiana Foroud,George W. Sledge +26 more
- 09 Sep 2014
TL;DR: A genetic variant in SV2C predicted clinically relevant bevacizumab-induced hypertension in two independent, randomised phase III trials.
30